Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Galimedix Therapeutics
Galimedix Therapeutics Overview
Galimedix Therapeutics is a phase-2 clinical-stage ophthalmic pharmaceutical company developing treatments based on a novel mechanism of action directed at the common cause of several neurodegenerative diseases: toxic oligomers of amyloid beta. Its focus is on two of the leading causes of blindness: dry macular degeneration of the retina and glaucoma.
The company is currently developing a novel treatment that delivers its patented small molecule drug with a unique mechanism of action via eye drops. Studies with Galimedix's eye drops in monkeys have demonstrated drug concentration quickly reaching more than 30 times estimated therapeutic levels in the retina of the closest model to human eyes. Compelling efficacy data from GAL-101 eye drops in relevant animal models has also demonstrated more than 90% neuroprotection, and the treatment has drawn the active support of more than a dozen experts in both glaucoma and dry age-related macular degeneration. These experts also support the design of the company's proposed phase-2 studies.
Galimedix Therapeutics, Inc.'s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen's Aducanumab
#Partners #Investment
May 8, 2019
www.globenewswire.com
Preclinical Studies Demonstrate Galimedix Therapeutics' Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models
#Investment, Expand
Feb 6, 2019
www.globenewswire.com
Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference
#Investment #Expand
Dec 11, 2018
www.globenewswire.com
Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer
#Management Changes
Oct 21, 2018
www.globenewswire.com
Galimedix Therapeutics, Inc. To Present at the BIO Investor Summit
Galimedix Therapeutics, Inc.'s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen's Aducanumab
#Partners #Investment
May 8, 2019
www.globenewswire.com
Preclinical Studies Demonstrate Galimedix Therapeutics' Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models
#Investment, Expand
Feb 6, 2019
www.globenewswire.com
Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference
#Investment #Expand
Dec 11, 2018
www.globenewswire.com
Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer
#Management Changes
Oct 21, 2018
www.globenewswire.com
Galimedix Therapeutics, Inc. To Present at the BIO Investor Summit
#Investment #Management Changes
View other companies you might be interested in
Galimedix Therapeutics Team
No Data, yet.
Sorry, no content found under this section.
View other companies you might be interested in
Connect with
What is the reason for connecting? *
Your company *
Company website (recommended)
Please enter a valid website
Your organization type *
Please enter a valid organization type
Your position *
Add invitation message
0/300
Sending invitation...
Invitation sent
You will be able to start a conversation once [Name] accepts it.